Good maths is needed to understand CMV data in glioblastoma

International Journal of Cancer

Volumn 134, Issue 12, 2014, Pages 2991-2992

  Wick, Wolfgang ^a,b   Wick, Antje ^a,b   Platten, Michael ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Im Neuenheimer Feld 400   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN EXPRESSION; CANCER PROGNOSIS; CANCER SURVIVAL; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; INTENTION TO TREAT ANALYSIS; LETTER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE;

ANIMALS; ANTIVIRAL AGENTS; BRAIN NEOPLASMS; GANCICLOVIR; GLIOBLASTOMA; HUMANS;

EID: 84898004577     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28614     Document Type: Letter

References (5)

1. Söderberg-Nauclér C, Rahbar A, Stragliotto G,. Survival in patients with glioblastoma receiving valganciclovir. N Engl J Med 2013; 369: 985-6.
2. Stragliotto G, Rahbar A, Solberg NW, et al. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study. Int J Cancer 2013; 133: 1204-13.
3. Stupp R, Mason W, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
4. Chinot O, Wick W, Mason W, et al. Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly-diagnosed glioblastoma: Mature progression-free survival and preliminary overall survival results in AVAglio. 17th Annual Meeting of the Society for Neuro-Oncology. Plenary Session 5. Abstract OT-03. Presented November 17, 2012.
5. Weller M, Pfister SM, Wick W, et al. Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol 2013; 14: e370-e379.